OPHT Ophthotech Corporation

3.33
+0.04  (1%)
Previous Close 3.29
Open 3.30
Price To book 2.73
Market Cap 120008814
Shares 36,038,683
Volume 95,332
Short Ratio 3.48
Av. Daily Volume 698,086

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171185050
  2. 8-K - Current report 171185042
  3. 8-K - Current report 171181131
  4. 8-K - Current report 171159471
  5. CT ORDER - Confidential treatment order 171091180

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a initial data due end of 2018.
Zimura
Wet age-related macular degeneration (Wet-AMD)
Phase 3 data released December 12, 2016 - primary endpoint not met. Data from third trial released August 14, 2017- primary endpoint not met.
Fovista
Wet age-related macular degeneration (Wet-AMD)
Phase 2b initial data due 2H 2019.
Zimura
Geographic atrophy

Latest News

  1. Report: Exploring Fundamental Drivers Behind Carter's, Southern Copper, ViaSat, Bruker, Fred's, and Ophthotech — New Horizons, Emerging Trends, and Upcoming Developments
  2. ETFs with exposure to Ophthotech Corp. : November 20, 2017
  3. Ophthotech (OPHT) Jumps: Stock Rises 11.9%
  4. Edited Transcript of OPHT earnings conference call or presentation 8-Nov-17 1:00pm GMT
  5. Vertex Gets CHMP Recommendation for Orkambi Label Expansion
  6. Ophthotech Corp. :OPHT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
  7. Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus
  8. Today’s Research Reports on Stocks to Watch: Ophthotech Corporation and HTG Molecular Diagnostics
  9. Ophthotech Soars After Third-Quarter Results -- Biotech Movers
  10. Ophthotech posts 3Q profit
  11. Ophthotech Reports Third Quarter 2017 Financial and Operating Results
  12. Ophthotech Corp. to Host Earnings Call
  13. Ophthotech Corporation to Report Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
  14. How Should You Think About Ophthotech Corporation’s (OPHT) Risks?
  15. How is the Age-Related Macular Degeneration Space Faring Now?
  16. Ophthotech Provides Update on Zimura® Complement Programs for Treatment of Eye Diseases
  17. Roche's Ophthalmology Drug Fails to Meet Primary Endpoint
  18. Roche shares decline 1.6% on news that late-stage study missed primary endpoint
  19. Why Is Ophthotech (OPHT) Up 7.4% Since the Last Earnings Report?

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171185050
  2. 8-K - Current report 171185042
  3. 8-K - Current report 171181131
  4. 8-K - Current report 171159471
  5. CT ORDER - Confidential treatment order 171091180
  6. 8-K - Current report 171026837
  7. S-8 - Securities to be offered to employees in employee benefit plans 171004854
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000507
  9. 8-K/A [Amend] - Current report 17981689
  10. 8-K - Current report 17981605